You are here: Industry Insights > Market News > Hikma intends to acquire assets in Egypt, Tunisia

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Toasted Coconut Powder

Coconut Milk Powder

Hikma intends to acquire assets in Egypt, Tunisia

expresspharmaJanuary 27, 2021

Tag: Hikma , GSK , Tunisia

Favorites

Hikma Pharmaceuticals said it was planning to buy GSK’s stake in some assets including the drugmaker’s pharma, consumer commercialisation and manufacturing business in Egypt and its drugs business in Tunisia.

The company, which supplies many generic drugs including anaesthetics, pain medications, sedatives, neuromuscular blocking agents and anti-infectives, said further talks with GSK will depend on the results of its due-diligence process.

Previous:Sanofi to produce 100 million Pfizer/BioNTech vaccine doses: CEO

Next:Misinformation, future of work among key pharma trends in 2021: GlobalData

Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China

ACN NewswireMay 07, 2025

Everest Medicines announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National Medical Products Administration (NMPA).

InnoCare’s Zurletrectinib Receives Priority Review from China’s NMPA

PharmaSourcesMay 06, 2025

HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress

ACN NewswireApril 25, 2025

Hikma intends to acquire assets in Egypt, Tunisia | Pharmasources.com

InnoCare Announces Approval of Orelabrutinib for the First-line Treatment of CLL/SLL in China

PharmaSourcesApril 27, 2025

InnoCare Pharma announced that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration (NMPA) for the first-line treatment of patients with chronic lymphocytic leukemia / small lymphocytic lymphoma.

996热re视频精品视频这里,国产又色又爽又高潮免费,精品自拍亚洲一区在线,久久久综合九色合综,国产精品亚洲综合一区在线观看

Hikma intends to acquire assets in Egypt, Tunisia

Related News

Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China

InnoCare’s Zurletrectinib Receives Priority Review from China’s NMPA

HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress

InnoCare Announces Approval of Orelabrutinib for the First-line Treatment of CLL/SLL in China

You may like
More>>

996热re视频精品视频这里,国产又色又爽又高潮免费,精品自拍亚洲一区在线,久久久综合九色合综,国产精品亚洲综合一区在线观看

Hikma intends to acquire assets in Egypt, Tunisia

Related News

Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China

InnoCare’s Zurletrectinib Receives Priority Review from China’s NMPA

HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress

InnoCare Announces Approval of Orelabrutinib for the First-line Treatment of CLL/SLL in China

You may likeMore>>

You may like
More>>